Below is a comparison of the biggest winners and losers in marijuana stocks this week, grouped by market cap and country. See whether your picks are outperforming or if you need to rebalance your portfolio.
The PotStocks weekly slide has officially come to an end. For the last three weeks, HMMJ has been falling, but in the first week of September, the industry finally showed some life with an 8% gain. Hopefully, this marks the end of the summer sorrows.
As the cannabis industry goes, this was a relatively quiet week. There was the same ever-darkening news from CannTrust of substantial layoffs and black-market seeds being used to grow pot. Somehow the stock managed to finish positive this week.
The biggest news probably came from Aurora’s block trade of their TGOD stake, which led to a 15% drop in the share price overnight. While it wiped out early-week gains, since that time the shares finished almost even with the $3.00 mark that was set. This suggests the market has absorbed the news well.
One surprising jump was from Tilray, whose stock rose 25%. According to The Street, “Tilray shares jumped on Tuesday after Cowen & Co. affirmed its outperform rating on the cannabis producer and distributor but sharply lowered its price target to $60 a share from $150.” Yes you read that right – shares jumped on a 60% downward price target revision – what a time to be alive.
Pot Stocks Group Performance
Canadian Pot Stocks – Large-Cap Weekly Performance
Canadian Pot Stocks – Large-Cap YTD Performance
Canadian Pot Stocks – Mid-Cap Weekly Performance
Canadian Pot Stocks – Mid-Cap YTD Performance
Canadian Pot Stocks – Small-Cap Weekly Performance
Canadian Pot Stocks – Small-Cap YTD Performance
U.S. Pot Stocks – Large-Cap Weekly Performance
U.S. Pot Stocks – Large-Cap YTD Performance
U.S. Pot Stocks – Mid-Cap Weekly Performance
U.S. Pot Stocks – Mid-Cap YTD Performance
U.S. Pot Stocks – Small-Cap Weekly Performance
U.S. Pot Stocks – Small-Cap YTD Performance
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.